Boehringer Ingelheim has completed the expansion of its biopharmaceutical manufacturing facility in Fremont, California. With a two-year investment totaling $ 228 million, the research-driven pharmaceutical company is creating 300 new jobs and increasing its worldwide bioreactor capacity to 290,000 liters.
Fremont/USA — The company announced that it was now well-positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as a contract manufacturer for other pharmaceutical and biopharmaceutical companies.
Dr. Uwe Bücheler, Head of the Biopharmaceuticals Business Unit, said that the completion of the expansion in Fremont marked another milestone in the manufacturer's biopharmaceutical growth strategy, with locations in the United States, Germany, Austria, and China are contributing to the development of biopharmaceuticals.
In 1987 Boehringer Ingelheim brought Actilyse, one of the first biological medicinal products for the treatment of stroke and acute myocardial infarction, onto the market with a development partner. Today, biopharmaceuticals make up around 40 % of the active ingredient candidates from the company's research pipeline. Biotech contract manufacturing experienced double-digit growth in the past year and consolidated its global market leadership. The company has an experience in manufacturing of 31 biopharmaceutical medicines for different customers worldwide.